October 1, 2024 AlzeCure’s abstract on ACD856’s anti-inflammatory effects to be presented at a leading Alzheimer’s conference
August 13, 2024 New scientific article on NeuroRestore ACD856 and its improved cognition and disease modification of Alzheimer’s disease
August 7, 2024 New results from AlzeCure’s pain project TrkA-NAM presented at the pain conference IASP 2024
July 18, 2024 AlzeCure Pharma carries out a directed share issue in follow-up to a previously given subscription commitment
June 13, 2024 New scientific article published on positive clinical results with Painless ACD440 against neuropathic pain
May 15, 2024 Eli Lilly’s and AstraZeneca’s former head of research Dr. Jan Lundberg elected as a new board member
May 13, 2024 AlzeCure reports anti-inflammatory effects with NeuroRestore ACD856 with relevance to Alzheimer’s leading to new patent application
April 25, 2024 The extraordinary general meeting of AlzeCure Pharma AB approved the decision on the new issue of shares
April 10, 2024 Eli Lilly’s and AstraZeneca’s former head of research Dr. Jan Lundberg invests in AlzeCure and is proposed for election to its board
March 7, 2024 AlzeCure presents new preclinical data with NeuroRestore ACD856 at leading Alzheimer’s conference
March 5, 2024 AlzeCure publishes clinical results supporting continued development of NeuroRestore ACD856 against Alzheimer’s
February 12, 2024 AlzeCure Pharma broadcasts live expert event on Alzheimer’s around highly current gamma-secretase modulators
February 6, 2024 AlzeCure gets Late Breaking abstract of new preclinical data with ACD856 accepted at AD/PD 2024 conference
January 31, 2024 AlzeCure CEO Martin Jönsson to present at the international investor conference BioCapitalEurope
January 29, 2024 AlzeCure selects drug candidate and enters next phase of development with TrkA-NAM ACD137 against severe pain
January 17, 2024 The government draws attention to Swedish Alzheimer’s research and together with the Swedish Alzheimer’s Foundation visit AlzeCure Pharma
